The Effect of Dapagliflozin on Renal Disease Progression

Diabetesincontrol.com

Klicken Sie hier, um Diabetesincontrol.com zu abonnieren

Kategorien: Gesundheit | Wohlfahrt Gesundheit Bildung Alter: 14 - 18 Jahr 19 - 30 Jahr 31 - 64 Jahre

Laden...

3 jahre vor

Html
Text

Plus: NAFLD screening; lifestyle modifications in children; more

Saturday, Nov. 28, 2020 : Issue #1084

TOP STORIES - Diabetes News & Research

The Effect of Dapagliflozin on Renal Disease Progression
Long-Term Effects of Lifestyle Modifications in Children with Normal Weight
NAFLD Screening Benefits

Letter from the Editor
Non-alcoholic fatty liver disease, NAFLD, is often talked about when we look at diabetes patients. Many studies have looked at the effects of NAFLD on patients with diabetes, and how this disease is a component of metabolic syndrome.
Unfortunately there are no ADA or AASLD guidelines for testing in type 2 patients, so oftentimes this test is not done. This week our South College Intern Shadrielle Robbins takes a look at a study that examines all possible combinations of testing in order to find out what is most cost effective; if the testing was worth the money spent on it; and if younger patients could benefit from testing sooner rather than later.
What she found out may totally surprise you.
*****************************
We can make a difference!
*****************************
Dave Joffe
Editor-in-chief

Did You Know? The Relationship Between Diabetes And Death

We are experiencing a paradigm shift in treating diabetes mellitus when it comes to preventing cardiac failure and stroke, as most patients with diabetes do not die from diabetes, but cardiac failure and stroke.
Randomized trials have shown that if you treat hypertension in people with diabetes mellitus who had a stroke, you can decrease the risk for a recurrent stroke by about 40%. If patients with diabetes and high cholesterol get a statin, the chance for a recurrent stroke is reduced by 21%.
Diabetes has two consequences: small- and large-vessel disease. Small-vessel disease affects the retina, kidney, and brain. Large-vessel disease leads to a higher risk for ischemic stroke, myocardial infarction, and peripheral arterial disease. We now have two new classes of drugs, sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists. In six randomized trials where SGLT2 inhibitors were compared with placebo, they significantly impacted cardiac failure and associated deaths. GLP-1 receptor agonists not only reduce blood glucose and body weight, but they also have a positive impact on the risk for major adverse cardiac events such as myocardial infarction, stroke, and vascular death. Two randomized controlled trials of GLP-1 receptor agonists showed that they had a significant benefit in preventing stroke, with one study indicating that they even impacted cognitive impairment in patients with diabetes mellitus.

Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters:

Abdullah Al-Ajmi, PharmD Candidate, Skaggs School of Pharmacy and Pharmaceutical Sciences

Tarshay Boyd, PharmD. Candidate, LECOM School of Pharmacy

Louise Brown, PharmD Candidate, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences

Destiny Reed, PharmD. Candidate, Florida A&M College of Pharmacy and Pharmaceutical Sciences

Shadrielle Robbins, PharmD Candidate, South College School of Pharmacy

About LaterPay: You will notice that some of our articles are now marked with a small credit card icon. This means you will be asked to pay a small fee to access the full article text (the cost is $0.39 per article, and you will be charged only after you have reached $5.00 in article views). The costs of producing a newsletter like Diabetes in Control have been increasing, which is why we are asking our readers to help support our ability to continue to bring you quality information about diabetes through charging a minimal price to read certain articles. Thank you for helping to support Diabetes in Control.

Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
810 Bear Tavern Road Suite 102
Ewing, NJ, 08628
USA
www.diabetesincontrol.com

©2020 HIPER, LLC. All rights reserved.
This email was sent by eHealthcare Solutions on behalf of: Diabetes In Control
810 Bear Tavern Rd, Suite 102
Ewing, NJ, 08628, United States
DiabetesInControl.com | Contact Us
Subscription Center | Update Profile
Unsubscribe

Teilen auf

Laden...

Weitere Newsletter von Diabetesincontrol.com

Laden...

Andere Kategorien anzeigen

Gesundheit | Wohlfahrt Gesundheit Bildung

The Effect of Dapagliflozin on Renal Disease Progression

Saturday, Nov. 28, 2020 : Issue #1084

TOP STORIES - Diabetes News & Research

TOP STORIES - Diabetes News and Research

Did You Know? The Relationship Between Diabetes And Death

Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletters:

Teilen auf

Weitere Newsletter von Diabetesincontrol.com

Verwandte Newsletter

Andere Kategorien anzeigen